Since high expression of UBASH3B confers poor prognosis in ER+ breast cancer and tamoxifen is a first-line drug for the management of ER+ patients, UBASH3B expression may be associated with tamoxifen efficacy. This evidence concerns the gene ESR1 and breast cancer.